enx-102
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 3, 2023 (NCT05749055)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Gamma-amino-N-butyrate transaminaseACTIVATOR
ABAT activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07193563 | Phase 2 | Sep 5, 2025 | Engrail Therapeutics INC |
| NCT06653296 | Phase 2 | Dec 31, 2024 | Engrail Therapeutics INC |
| NCT05749055 | Phase 2 | Jul 3, 2023 | Engrail Therapeutics INC |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Engrail Therapeutics INC | For profit | 3 | 3 | 1 | 2023 |
1 organizations
Page 1 / 1